ImmunoBody is named as an intervention in 2 current clinical trials in our UK and USA registers. None are recruiting at the moment. The most common phase is Phase 3. The lead sponsor is Scancell Ltd. The most-studied condition is Melanoma (Skin Cancer).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
NCT07815574 · ClinicalTrials.gov ↗ · Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma
|
Phase 3 | Not yet open | Scancell Ltd | UK, USA |
|
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
NCT04079166 · ClinicalTrials.gov ↗ · Malignant Melanoma, Melanoma (Skin), Melanoma Stage III
|
Phase 2 | Active, closed | Scancell Ltd | UK |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Scancell Ltd | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in UK | 2 | 0 |
| Clinical trials in USA | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our UK and USA registers name ImmunoBody (also registered as ISCIB1) as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Scancell Ltd. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how ImmunoBody works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ImmunoBody works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ImmunoBody (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.